
Adding Olaparib and Durvalumab Improved PFS in Patients Newly Diagnosed With Advanced Ovarian Cancer
Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation.





























